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The interleukin-3 (IL-3) receptor is a cell-surface heterodimer that links the haemopoietic,
vascular and immune systems and is overexpressed in acute and chronic myeloid leukaemia
progenitor cells. It belongs to the type I cytokine receptor family in which the α-subunits
consist of two fibronectin III-like domains that bind cytokine, and a third, evolutionarily
unrelated and topologically conserved, N-terminal domain (NTD) with unknown function.
Here we show by crystallography that, while the NTD of IL3Rα is highly mobile in the
presence of IL-3, it becomes surprisingly rigid in the presence of IL-3 K116W. Mutagenesis,
biochemical and functional studies show that the NTD of IL3Rα regulates IL-3 binding and
signalling and reveal an unexpected role in preventing spontaneous receptor dimerisation.
Our work identifies a dual role for the NTD in this cytokine receptor family, protecting against
inappropriate signalling and dynamically regulating cytokine receptor binding and function.
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Interleukin (IL)-3 is a tightly regulated pleiotropic cytokineproduced mainly by activated T lymphocytes that stimulatesthe production and function of multiple haematopoietic cell
types as well as cells involved in the immune response such as
dendritic cells1,2. Beyond haemopoiesis and immunity, IL-3 has
also been shown to play a role in other biological systems such as
angiogenesis3 and in the development of the central nervous
system4,5. In recent years, the IL-3 receptor system has come
under the spotlight because stem/progenitor cells from patients
with acute myeloid leukaemia (AML) overexpress the IL-3
receptor α-subunit (IL3Rα) and this is associated with reduced
patient survival3,6–9. IL3Rα is also overexpressed in chronic
myeloid leukaemia (CML) providing a promising target for
therapy10. Hence, there are ongoing efforts to understand how the
IL-3 receptor signals and to develop new therapies in AML and
CML based on appropriately targeting IL3Rα.
IL-3 is a member of the beta common (βc) cytokine family,
which also includes granulocyte-macrophage colony-stimulating
factor (GM-CSF) and IL-5. These cytokines signal through het-
erodimeric cell-surface receptors that are expressed at low levels and
comprise a cytokine-specific α-subunit and the shared βc subunit1.
Activation of the IL-3 receptor is thought to involve sequential
assembly of a receptor signalling complex whereby the critical step
is the initial binding of IL-3 to IL3Rα2,11–13, followed by recruit-
ment of βc and the assembly of a high order complex which, by
analogy with the GM-CSF receptor14, would bring JAK2 molecules
together to trigger downstream signalling. Interestingly, the initial
binding of the βc cytokines to the α-subunits is with low affinity that
varies widely among the three receptors, yet the high-affinity
binding achieved when βc is present is the same (KD ~200 pM) for
all three cytokines. IL-3 is remarkable because of its very low affinity
for IL3Rα (KD ~100–200 nM), much lower than the affinity of
GM-CSF (KD 2–10 nM) or IL-5 (KD 1–2 nM) for their respective
α-subunits. However, it is not known how IL3Rα recognises IL-3
nor how the IL-3 binary complex overcomes such a low affinity
interaction and yet achieves the same high affinity as GM-CSF
and IL-5 in the presence of βc. Previous studies have demonstrated
that IL-3 K116 variants, in particular the K116W variant, have
higher affinity for IL3Rα compared to wild-type IL-3 and
enhanced proliferative activity15–17. Mutant cytokines with higher
affinity for their receptors and/or higher functional potency have
been dubbed ‘superkines’18. A molecular explanation for how a
single mutation converts IL-3 into a superkine has not been
forthcoming.
We have recently solved the structure of the extracellular
region of IL3Rα bound to the blocking antibody CSL362 that is
currently in clinical trials for AML11. The extracellular region of
IL3Rα comprises three fibronectin type III (FnIII) domains: an
Ig-like N-terminal FnIII domain (NTD) followed by a pair of
FnIII domains: domain 2 (D2) and domain 3 (D3). Interestingly,
two CSL362:IL3Rα complexes were observed, very similar in their
overall molecular arrangements, except for the orientation of the
IL3Rα NTD. The crystals revealed two distinct IL3Rα con-
formations, an ‘open’ form in which the angle between the NTD
and D2 domains of IL3Rα is ~95°, and a ‘closed’ form in which
the angle between the NTD and D2 domains is ~55° and is
comparable to the ‘wrench-like’ conformation11 reported for the
related cytokine receptors GMRα19, IL5Rα20,21, IL13Rα122 and
IL13Rα223. The reason for these two conformations is unclear but
it has been hypothesised that the NTD of IL3Rα, like other
members of the type I cytokine receptor family, may provide
molecular flexibility to facilitate cytokine recognition and allow
appropriate presentation of cytokine to the signalling subunits of
these receptor families. Intriguingly, the NTD is omitted in one
isoform of IL3Rα (IL3Rα SP2) and although not essential, the
NTD contributes significantly to wild-type IL-3 function24.
Here we present the crystal structures of the IL3Rα extra-
cellular domains bound to wild-type IL-3 and to the IL-3 K116W
superkine. The structures show the detailed molecular interfaces
between IL3Rα and ligand and, in particular the mechanism of
IL3Rα NTD engagement with the cytokine. All-atom explicit-
solvent molecular dynamics (MD) simulations reveal that the
IL3Rα NTD is highly mobile and remains so when bound to wild-
type cytokine, but becomes relatively rigid when bound to IL-3
K116W, indicating that the NTD interaction can be distally
regulated. Structure-guided mutagenesis, along with functional
and biochemical studies, establish a critical role for the IL3Rα
NTD in optimising IL-3 binding and function and in preventing
spontaneous receptor heterodimerisation with βc. Given their
overall structural conservation, the NTD may perform similar
roles in other members of the type I cytokine receptor family.
Results
IL-3 receptor recognises cytokine differently. We have deter-
mined the crystal structure of IL-3 bound to its receptor α-sub-
unit, IL3Rα, to 2.7-Å resolution (Methods, Table 1, Fig. 1,
Supplementary Fig. 1). Two complexes were found in the asym-
metric unit and they overlay closely (Supplementary Fig. 2a) with
root-mean-square deviation (RMSD) of the Cα atoms of 0.7 Å
(additional detail in Supplementary Note 1). IL3Rα residues P25
to F96 define the Ig-like NTD, residues E108 to F202 define D2
and the third FnIII domain, D3, consists of residues T209 to
D294. D2 and D3 constitute the cytokine recognition module
(CRM) (Fig. 1a). IL3Rα contains N-linked glycans at N80,
N109 and N218 (Fig. 1a) that are required for optimal IL3Rα
expression (Supplementary Fig. 3a, b and see additional detail in
Supplementary Note 1).






Space group P6522 P61
Cell dimensions
a, b, c (Å) 132.0, 132.0, 210.6 106.5, 106.5, 96.1
α, β, γ (°) 90, 90, 120 90, 90, 120
Resolution (Å) 48.1–2.7 (2.83–2.7) 48.1–2.4 (2.40–2.39)
Rmeas 0.19 (0.83) 0.08 (0.69)
Rpim 0.09 (0.39) 0.02 (0.17)
I/σI 25.7 (4.8) 19.7 (3.4)
CC1/2 0.99 (0.81) 0.99 (0.74)
Completeness (%) 100 (100) 99.5 (97.5)
Redundancy 8.1 (8.5) 16.1 (16.1)
Refinement
No. of reflections 13,304 25,439





Main chain 44.5 70.0




Bond lengths (Å) 0.02 0.03
Bond angles (°) 2.3 2.5
Data were collected from a single crystal per complex. Values in parentheses are for highest
resolution shell. Related to Figs. 1, 2, 4, 5, Supplementary Figs. 1, 2 and 4
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02633-7
2 NATURE COMMUNICATIONS |  (2018) 9:386 |DOI: 10.1038/s41467-017-02633-7 |www.nature.com/naturecommunications
The three IL3Rα FnIII domains adopt a ‘wrench-like’
conformation that wraps around the four helical bundle of IL-
3. The hinge region between the D2 and D3 domains has an
elbow angle of ~100°, which is within the range observed in
related type I cytokine receptor structures11,19–23. The elbow
angle between D2 and NTD is ~65° and a disulphide bond
(C76–C195) provides an additional covalent interaction between
these domains that is not found in related receptors. The
receptor component of the IL-3:IL3Rα complex is similar to the
IL3Rα structures previously determined in complex with an
antibody11; the CRMs are essentially identical (RMSD over the
Cα atoms is 0.5 Å); however, the angle of the NTD with respect
to the CRM in the IL-3:IL3Rα complex lies between the angles


















































































Fig. 1 Crystal structure of the IL-3 binary complex. a The structure of IL3Rα (coloured blue-grey in all panels) bound to the four α-helical bundle of IL-3
(coloured purple in all panels). The β-strands that make up the three FnIII domains (NTD, D2 and D3) and the N- and C-termini are labelled. The cysteine
residues in IL3Rα are represented as yellow spheres and the bound sugars at N80, N109 and N218 of ILRα are shown as sticks. The mutated N212Q residue
is shown as red spheres. D197 is represented as green spheres. b A close-up view highlighting key interactions between IL-3 and the IL3Rα NTD (site 1b).
Hydrogen bonds are shown as black dashed lines in all panels. c A close-up view highlighting key interactions between IL-3 and the IL3Rα D2–D3 linker
region (part of site 1a). d A close-up view highlighting key interactions between IL-3 and the IL3Rα D3 (part of site 1a). Together, c and d define the
complete site 1a
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structures (Supplementary Fig. 2b and additional detail in
Supplementary Note 1).
IL3Rα contacts IL-3 through an interface containing two
distinct interaction sites, site 1a and site 1b. The entire interface
consists of 12 hydrogen bonds, 4 salt bridges and 16 residues
involved in van de Waals interactions; a complete list of these
interactions are detailed in Supplementary Table 1. Site 1a
comprises the interactions between cytokine and the IL3Rα CRM
and corresponds to the classical site 1 of simpler type I
homodimeric cytokine receptors25. The EF loop in D2, the
D2–D3 linker region and the BC and FG loops of D3 define the
IL3Rα contribution to site 1a (Fig. 1c, d, Supplementary Fig. 1c).
Site 1b, the specific molecular interaction between cytokine and
the IL3Rα NTD, is unique among the βc and IL-13 receptors and
comprises the C-, D- and E-strands and the DE and EF loops of
the IL3Rα NTD (Fig. 1b) that interact with IL-3 via the α2-helix,
and the CD loop (Fig. 1a, Supplementary Figs. 1c, 4a).
The most surprising difference between the IL-3 binary
complex and related cytokine complexes is the manner in which
IL-3 interacts at site 1b. In all related receptor complexes, the
cytokine interacts with the receptor subunit NTD via a β-sheet
hydrogen bonding network between the D-strand of the NTD
and the β2-strand of the cytokine (Fig. 2, Supplementary Fig. 4a
and additional detail in Supplementary Note 1). Unlike GM-CSF,
IL-4, IL-5 or IL-13, IL-3 does not have a structural equivalent to
the β2-strand (Fig. 2, Supplementary Fig. 4a). In the IL-3 binary
complex, the D-strand of the IL3Rα NTD is closest to the two-
turn IL-3 α2-helix (residues N41-M49, located on the AB loop)
and the CD loop. IL-3 makes only five polar interactions with the
IL3Rα NTD; one between the side chain of IL-3 H95 and the
backbone carbonyl of IL3Rα A62 and a second between IL-3 D44
(located on the α2-helix) and the hydroxyl group of IL3Rα Y58
(Figs. 1b, 2a). In addition, a network of three polar interactions





















































































Fig. 2 Comparison of IL3Rα site 1b interactions to related cytokine receptor complexes. aWild-type IL-3:IL3Rα binary complex. b IL-5:IL5Rα binary complex
(PDB ID: 3VA2, 3QT220, 21). c GM-CSF:GMRα binary complex (PDB ID: 4RS119). d IL-13:IL13Rα1 component of the ternary complex (PDB ID: 3BPO22). e IL-
13:IL13Rα2 binary complex (PDB ID: 3LB623). f IL-4:IL13Rα1 component of the ternary complex (PDB ID: 3BPN22)
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further stabilises the IL-3:IL3Rα NTD (site 1b) interaction. The
IL-3 α2-helix tucks into a crevice between the D-strand and the
EF loop of the IL3Rα NTD and it is a unique point of stabilisation
that does not occur in GM-CSF, IL-4, IL-5 or IL-13 (Fig. 2,
Supplementary Fig. 4a). A detailed analysis of the site 1a and site
1b interaction surfaces in the IL-3:IL3Rα binary complex
structure shows that multiple IL-3 residues contribute to IL3Rα
binding (Supplementary Table 1).
NTD contributes to optimal IL-3 binding and signalling. We
have recently identified functional roles for a distinct set of IL3Rα
residues in mediating direct IL-3 binding and from our crystal
structure we observe that these residues are distributed across
both site 1a and site 1b (Fig. 1, Supplementary Table 1)11. In site
1a, Q178 in the EF loop of D2, V201 and S203 in the D2/D2–D3
linker region, N233 in the BC loop of D3 and E276, R277 and
Y279 in the F-strand/FG loop of D3—all have a functional role.
In site 1b, the key functional residues are K54 in the C-strand,
Y58 in the D-strand and G71 and A72 in the EF loop of the NTD.
We previously used surface plasmon resonance and the soluble
form of the α-subunit (ie, extracellular domain only, sIL3Rα) to
investigate the contribution of these IL3Rα residues to IL-3
binding11. Compared to wild-type sIL3Rα (KD = 220 nM), alanine
mutations of Y58, G71 in the NTD, and E276 or Y279 in site 1a
abolished measurable IL-3 binding (KD> 5000 nM), while alanine
mutations of site 1a Q178, V201, S203, N233 and R277 produced
modest reductions in IL-3-binding affinity (KD = 580–2250 nM).
These differences in IL-3 binding became masked when full-
length receptor mutants were co-expressed with βc on COS cells
and wild-type high-affinity binding was restored11 while also
demonstrating that the loss of measurable IL-3 binding does not
neccessarily mean abolition of IL-3 interaction. Despite this,
CTLL-2 cells co-expressing βc and many of the IL3Rα mutants
(Supplementary Fig. 5) are significantly less responsive to IL-3
stimulation in cell proliferation studies than cell expressing wild-
type IL3Rα (Fig. 3, Supplementary Table 2). In particular,
mutation of residues K54, Y58, F70, G71 and A72 in the NTD all
led to significant reductions in IL-3 function (ED50 = 0.18–46.6
ng ml−1) compared to wild-type IL3Rα (ED50 = 0.028 ng ml−1). In
the IL3Rα CRM region, only mutation of Q178, V201, Q204,
N233, E276 and Y279 led to a significant reduction in IL-3
function (Fig. 3, Supplementary Table 2). The reduction in IL-3
signalling we observe for these IL3Rα mutations may arise as a
result of reduced IL-3 binding to IL3Rα, but may also reflect
subtle alterations in the engagement of βc in IL-3 signalling
complexes utilising mutant IL3Rα. Mutation of the buried F70
residue has a drastic effect on IL-3 responsiveness (ED50 = 46.6
ng ml−1); however, this may be attributed to a major reduction in










































































































** * * * * * * **nsnsnsns nsns
Fig. 3 IL3Rα site 1b residues are a functional hotspot in mediating IL-3 signalling. Functional activity of IL3Rα mutants was measured in a wild-type IL-3 or b
IL-3 K116W dose–response proliferation assays using CTLL-2 cell lines transduced to co-express the βc subunit with either wild-type or mutant forms of
IL3Rα. The identity of each IL3Rα mutant is shown along with the substituted residue (m). Half-maximal responses (ED50) were calculated from each
experiment and averaged. The dashed line represents the response from cells expressing wild-type IL3Rα. Errors represent SEM. Statistical significance of
differences in functional response between wild-type IL3Rα and the mutant forms of IL3Rα (p) was determined using a two-tailed unpaired t test and are
shown as black asterisks above the data for each mutant. Statistical significance of differences in functional response between wild-type IL-3 and IL-3
K116W (p) was also determined using a two-tailed unpaired t test and are shown as blue asterisks between data sets a and b. ns p> 0.05, *p< 0.05, **p<
0.01, ***p< 0.001, ****p< 0.0001
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These experiments identify multiple residues in IL3Rα that are
distributed across site 1a and site 1b, which contribute
significantly to IL-3 function.
IL3Rα recognises IL-3 K116W via a network of interactions.
To further explore the role of site 1 in IL-3 binding and signalling,
we determined the crystal structure of IL-3 K116W bound to
IL3Rα at 2.4-Å resolution (Methods, Table 1, Supplementary
Fig. 1). The IL-3 and IL-3 K116W binary complex structures are
essentially identical (Supplementary Fig. 2b) with an overall
RMSD over the Cα atoms of 0.6 Å (RMSD for IL3Rα is 0.5 Å and
for IL-3 is 0.3 Å). The cytokine buried surface area is similar in
both complexes (1150 Å2 for IL-3 vs 1166 Å2 for IL-3 K116W),
with close surface complementarity values (Sc = 0.69 for IL-3 vs
0.71 for IL-3 K116W) and a similar number of polar interactions
between the cytokine and IL3Rα (11 hydrogen bonds (one less
than wild type), 5 salt bridges (one more than wild type)).
Not surprisingly, the most significant differences between the
wild-type IL-3 and IL-3 K116W structures occur within the
vicinity of residue 116 (Fig. 4). Within the cytokine itself, the
single-turn α1-helix located on the wild-type IL-3 AB loop unfurls
slightly in IL-3 K116W (Supplementary Fig. 4b, d) to allow F37 to
interact via edge-to-face π–π interactions with W116, which in turn
interacts with F113 (also via edge-to-face π–π interactions). The π–
π interaction network formed between F37-W116-F113 stabilises
the cytokine AB loop and reduces the loop’s overall mobility as
assessed by comparisons of the Cα RMSD for the cytokines alone
(200 ns MD simulation, Supplementary Fig. 4b, c) and Cα contact
distances between F37, F113 and K/W116 in the binary complexes
(100 ns MD simulations, Supplementary Fig. 7b, c) (additional
detail in Supplementary Note 1). In the wild-type IL-3 binary
complex, the IL-3 K116 side chain points directly into an IL3Rα
hydrophobic pocket lined by residues Q204, N233, V278, Y279
and F281, and is further capped by F37 in IL-3 (Fig. 4a, c). The IL-
3 K116 side chain is stabilised by polar interactions with S203,
Q204 and N233 in IL3Rα, and N120 in IL-3. In contrast, the
W116 side chain of IL-3 K116W slots into a groove formed by
Q204 and Y279 of IL3Rα, and forms edge-to-face π–π interactions
with F37 and F113 in IL-3, and Y279 and F281 in IL3Rα. This
results in the IL-3 K116W side chain sitting snuggly in a site 1a
pocket formed by F37, T112, F113, T117, E119 and N120 of IL-3
and S203, Q204, N233, E276, V278 and Y279 of IL3Rα (Fig. 4b, d).
Additional interactions with the IL-3 K116W side chain also have a
downstream effect on the adjacent C-terminal end of helix D in IL-
3, which is involved in van der Waals contacts with IL3Rα via
residues E119, A121 and A123.
Differing effects of site 1 residues on IL-3 K116W function. We
assessed the impact of IL3Rα site 1 mutations on IL-3 K116W
function using the CTLL-2 cell lines co-expressing βc and IL3Rα
mutants (Fig. 3, Supplementary Table 2). In general, mutations of
IL3Rα site 1 residues had less impact on IL-3 K116W function
than for wild-type IL-3. We observed that mutation of residues
K54, A72, Q178, V201, Q204 and E276A led to significant
reductions in IL-3 K116W function (ED50 = 0.044–0.29 ng ml−1)
compared to wild-type IL3Rα (ED50 = 0.018 ng ml−1). As for
wild-type IL-3, the drastic impact of the IL3Rα F70A mutation on
IL-3 K116W responsiveness (ED50 = 18.8 ng ml−1) can be largely
attributed to reduced IL3Rα F70A expression levels (Fig. 3,
Supplementary Fig. 5, Supplementary Table 2).
IL3Rα S203, Q204, N233 and Y279 all interact directly with
both K116 of IL-3 and W116 of IL-3 K116W (Fig. 4,
Supplementary Table 1). Interestingly, both cytokines display
significantly reduced functional activity on CTLL-2 cells expres-
sing the IL3Rα Q204A mutant (Fig. 3, Supplementary Table 2). In
contrast to Q204, mutation of S203 does not affect the function of
either cytokine while mutation of N233 or Y279 significantly
reduces the function of wild-type IL-3 only suggesting that these
residues directly influence the K116/W116 cytokine interaction.









































Fig. 4 Structure of IL3Rα bound to IL-3 K116W. a Close-up view of the environment around IL-3 K116 in site 1a of the wild-type IL-3 binary complex. Colour
scheme as described for Fig. 1b–d. b Close-up view of the environment around W116 in site 1a of the IL-3 K116W binary complex. IL3Rα coloured blue-grey
and IL-3 K116W coloured yellow. c Residues around IL-3 K116 in the wild-type IL-3 binary complex displayed as spheres to demonstrate the volume they
occupy and the residue packing at this site. d As for c, but for the IL-3 K116W binary complex
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interaction, such as V201, K235 or E276, preferentially reduced
wild-type IL-3 function (Supplementary Table 2) and suggests
that these residues indirectly influence the K116/W116 cytokine
interaction. We were surprised that many IL3Rα NTD mutations
(ie, site 1b) also preferentially reduced wild-type IL-3 function,
since the IL3Rα NTD residues are distal to site 1a and the
interaction with IL-3 K116/W116 (Figs. 1, 3, Supplementary
Table 2). These results suggest that the IL3Rα NTD plays a more
dynamic role in IL-3 recognition and function than was
previously anticipated.
We were also surprised that wild-type IL-3 and IL-3 K116W
were indistinguishable at stimulating the proliferation of CTLL-2
cells expressing IL3Rα and βc (ED50 = 0.028 ng ml−1 and 0.018 ng
ml−1 respectively, Supplementary Table 2). Similarly, we observed
that the binding affinity of wild-type IL-3 and IL-3 K116W to
CTLL-2 cells expressing IL3Rα and βc was indistinguishable (KD
= 0.34 nM vs 0.14 nM respectively, Table 2). Comparable binding
affinities were also obtained using COS cells transiently expres-
sing IL3Rα and βc (KD = 0.48 nM vs 0.43 nM respectively,
Table 2). In contrast, using the TF-1 human erythroleukaemic
cell line, IL-3 K116W displayed the expected superkine behaviour
with enhanced binding (KD = 0.35 nM vs 2.06 nM respectively,
Table 2) and function (ED50 = 0.008 ng ml−1 and 0.044 ng ml−1
respectively, Supplementary Fig. 6a) relative to wild-type IL-3.
Considering that endogenous IL-3 receptor expression is typically
low on primary cells compared to engineered cell lines
(Supplementary Fig. 6b), we wondered if this contributed to the
differences in IL-3 function. Using a TF-1 cell line engineered to
overexpress IL3Rα26 (Supplementary Fig. 6b), we observed that
wild-type IL-3 and IL-3 K116W are functionally indistinguishable
(ED50 = 0.005 ng ml−1 each, Supplementary Fig. 6a), and impor-
tantly, while wild-type IL-3 is significantly more potent
(approximately ninefold) on cells expressing high levels of
IL3Rα, IL-3 K116W is not. Surprisingly, wild-type IL-3 and IL-
3 K116W both display comparable and enhanced binding to TF-
1Hi cells (KD = 0.14 nM vs 0.065 nM respectively, Table 2)
perhaps reflecting differences in the IL-3 receptor in these cells.
Our results indicate that the binding and function of wild-type
IL-3 is positively influenced by the level of IL3Rα expression,
whereas IL-3 K116W is markedly less influenced in these cells.
Explanation for the enhanced binding of IL-3 K116W. The
crystal structures of wild-type IL-3 and IL-3 K116W bound to
IL3Rα are very similar (Fig. 4, Supplementary Fig. 2b) and yet the
ligand-binding affinity for these two complexes are very different.
Compared to wild-type IL-3, IL-3 K116W has enhanced binding
to full-length IL3Rα expressed on COS cells (KD = 140.6 nM vs
17.8 nM, respectively, Table 2) or to soluble IL3Rα (KD = 510 nM
vs 5.3 nM respectively12). The increased receptor affinity of IL-3
K116W is due to a combination of an increased association
constant and decreased dissociation constant12. Examination of
the wild-type IL-3 and IL-3 K116W conformational states by MD
simulations showed that IL-3 K116W was conformationally
restricted compared to wild-type IL-3 (Fig. 5, Supplementary
Figs. 4b, c, 7a–c). The reduced conformational flexibility of IL-3
K116W, together with the W116 side chain slotting into a site 1a
pocket (Fig. 4b, d), could account for the increased association
constant of the IL-3 K116W superkine.
We have previously hypothesised that the IL3Rα NTD is a
highly mobile domain as IL3Rα can exist in open and closed
conformations based on differences in NTD placement in the
crystal structure11. IL3Rα transitioning to the closed conforma-
tion was proposed to occur upon binding of IL-3 to site 1a and
through the resultant engagement of site 1b in the NTD, lead to
reduced IL-3 dissociation. The closed IL3Rα conformation is very
similar to the conformation observed in the binary complex
crystal structures herein (Supplementary Fig. 2b). Interestingly,
the smaller root-mean-square fluctuation of the cytokine NTD
Cα atoms and the reduced interatomic distance between IL-3
E43–IL3Rα K54 and IL-3 D44–IL3Rα Y58 demonstrates that the
IL-3 K116W binary complex has a reduced mobility compared to
the wild-type IL-3 binary complex (Fig. 5, Supplementary Fig. 7h,
i). When overlaid via the CRM (ie, D2–D3), the conformational
stability of the IL3Rα NTD is increased in the wild-type IL-3
binary complex and is most pronounced in the IL-3 K116W
binary complex compared to the unliganded (ie, apo) form of
IL3Rα (Fig. 5a, b). The reduced mobility of the IL-3 K116W
binary complex can also be visualised by the alignment of 10 ns
snapshots from the binary complex MD simulations via the
cytokine (left hand images in Fig. 5c, d). The conformational
variability of IL3Rα over the 100 ns simulation timeframe is far
smaller for the IL-3 K116W than the wild-type IL-3 binary
complex.
Observing the decreased conformational mobility of IL3Rα
NTD in the IL-3 K116W binary complex, we investigated the
contribution of the NTD as a whole by examining IL3Rα SP2, a
Table 2 Enhanced site 1a interactions do not fully compensate for the loss of site 1b binding interactions through the NTD
Wild-type IL-3 IL-3 K116WCell Receptor subunits
n KD (nM) p n KD (nM) p
P
CTLL-2 IL3Rα + βc 2 0.34± 0.03 — 2 0.14± 0.01 — —
TF-1 Endogenous 4 2.06± 0.35 — 3 0.35± 0.12 — 0.006
TF-1Hi Overexpressed IL3Rα 7 0.14± 0.02 <0.0001 6 0.065± 0.006 0.003 0.004
COS IL3Rα + βc 15 0.48± 0.05 — 6 0.43± 0.09 — 0.98
COS IL3Rα SP2 + βc 10 7.61± 0.97 <0.0001 6 2.98± 0.87 0.011 0.004
COS IL3Rα C76A,C195A + βc 8 1.10± 0.31 0.009 6 0.94± 0.26 0.11 0.69
COS IL3Rα D197L + βc 6 4.37± 0.85 <0.0001 4 1.60± 0.09 <0.0001 0.02
COS IL3Rα 8 140.6± 16.9 — 6 17.8± 5.8 — <0.0001
COS IL3Rα SP2 3 N.B. — 6 N.B. — —
COS IL3Rα C76A,C195A n.d. 4 N.B. — —
COS IL3Rα D197L n.d. 4 N.B. — —
Binding of wild-type IL-3 or IL-3 K116W to cells expressing the indicated IL-3 receptor subunits was measured in saturation binding assays using radioiodinated cytokine60, 66. The CTLL-2 cell line
expresses full-length IL3Rα and βc was used as a basis for functional studies of IL3Rα mutants. The human TF-1 cell line or its derivative, TF-1 Hi that expresses high levels of IL3Rα as a result of being
transduced with a lentivirus encoding human IL3Rα, were used as a model of human AML. COS cells were transfected with plasmids encoding wild-type, D197L or C76A,C195A forms of full-length IL3Rα
or IL3Rα SP2, alone or together with βc. Errors represent SEM from the indicated number (n) of experiments or SD for n< 3. Statistical significance of differences in binding between TF-1 and TF-1Hi or
wild-type IL3Rα and the mutant forms of IL3Rα (p) or between IL-3 and IL-3 K116W (P) was determined using a two-tailed unpaired t test. Related to Figs. 3, 4, 5, 6, Supplementary Figs. 4, 6, 8 and
Table 3
n.d. not done, N.B. no binding
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splice variant of IL3Rα lacking the NTD24 (Supplementary
Fig. 1c) and with no measurable binding to IL-3 (Table 2).
Emphasising the critical role played by the NTD, we also
observed no measurable binding of IL-3 K116W to cells
expressing IL3Rα SP2 (Table 2). To assess the effect of the
NTD upon cytokine:IL3Rα complex stability, the IL3Rα NTD in
both binary complexes was truncated and the N-terminal residues
mutated in silico to those in the published SP2 sequence
(Supplementary Fig. 1c)24. When 10 ns snapshots from the 100
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type IL-3, there was little difference in the conformational
variability of wild-type or SP2 IL3Rα (Fig. 5c). However, the
stabilising role of the NTD is apparent in the simulations of the
IL-3 K116W binary complexes (Fig. 5d).
NTD prevents spontaneous receptor dimerisation. We next
examined what elements in the IL3Rα NTD were important to
support its correct conformation to maximise IL-3 binding and
signalling. Our previous crystal structure of IL3Rα complexed to
an antibody11 and the structure of IL3Rα complexed to IL-3
presented here (Fig. 1a) indicated that the IL3Rα NTD domain is
constrained by a disulphide bond between C76 in the NTD and
C195 in D2, and by a hydrogen bond between S74 in the NTD
and D197 in D2. We therefore investigated if the functional
contribution of the IL3Rα NTD was influenced by mutations that
retain the NTD but perturb its presentation to IL-3. The double
mutation C76A and C195A abolished the disulphide bond and
was therefore predicted to produce IL3Rα with a tethered but
highly mobile NTD. Similarly, the IL3Rα mutation D197L was
predicted to fill a pocket between the NTD and D2 and, through
steric interference, force IL3Rα to adopt an open-like con-
formation hence also impairing site 1b interactions11. MD
simulations (75 ns) of the IL3Rα C76A,C195A and IL3Rα D197L
mutants suggest an increased mobility for the NTD in both cases
(Fig. 6a). Breaking the IL3Rα NTD-D2 inter-domain disulphide
bond results in the NTD twisting laterally away from the con-
formations adopted by the apo wild-type IL3Rα (Fig. 6a, b, d).
Increasing the bulk of residue 197 forces the NTD away from D2
and the distance between the S74–L197 Cα atoms for the IL3Rα
D197L mutant is similar to that observed for the open apo wild-
type IL3Rα (Fig. 6a, c, e). Thus, the IL3Rα C76A,C195A and
IL3Rα D197L mutations are both predicted to exhibit ‘SP2-like’
activities as the NTD is displaced (Fig. 6d, e) and no longer plays
a stabilising role in cytokine binding.
We were unable to detect direct binding of IL-3 K116W to
COS cells expressing the IL3Rα C76A,C195A or IL3Rα D197L
mutants, which was in contrast to the relatively high-affinity
binding we observed on cells expressing full-length IL3Rα but
comparable to the lack of direct binding we observed for the
IL3Rα SP2 isoform (Table 2). When co-expressed with βc, IL3Rα
SP2 and IL3Rα D197L displayed significantly reduced binding
affinities for wild-type IL-3 and IL-3 K116W (Table 2). For IL3Rα
C76A,C195A, there was a modest but significant reduction in
binding affinity for wild-type IL-3 but not IL-3 K116W (Table 2).
To examine the functional capacity of the constrained NTD
mutants, we examined the response of mouse FDH cells
expressing these receptors. Cells co-expressing βc and IL3Rα
SP2, IL3Rα C76A,C195A and IL3Rα D197L proliferated in
response to wild-type IL-3 and IL-3 K116W stimulation but with
reduced potency compared to cells expressing full-length IL3Rα
(ED50 = 0.29 ng ml−1 and 0.37 ng ml−1 respectively, Table 3). Cells
expressing IL3Rα SP2 and IL3Rα C76A,C195A had comparable
functional responses to wild-type IL-3 (ED50 = 6.94 ng ml−1 and
12.17 ng ml−1 respectively, Table 3) and IL-3 K116W (ED50 =
2.19 ng ml−1 and 2.51 ng ml−1 respectively, Table 3). In contrast,
cells expressing IL3Rα D197L displayed a modest reduction in
cell proliferation to both wild-type IL-3 and IL-3 K116W (ED50 =
1.71 ng ml−1 and 0.60 ngml−1 respectively, Table 3). Therefore,
elimination of the C76–C195 disulphide bond that constrains
NTD mobility or substitutions at D197 that prevent proper
engagement of the NTD, produce full-length IL3Rα that has
functional similarities with IL3Rα SP2. Modest improvements in
binding affinity (Table 2) and potency (Table 3) for IL-3 K116W
relative to wild-type IL-3 are consistent with IL-3 K116W having
an enhanced interaction with IL3Rα D2–D3. Collectively, these
results demonstrate that the NTD interaction with IL-3 is
exquisitely sensitive to conformational changes.
We next examined whether the IL3Rα NTD was important for
receptor heterodimerisation and tyrosine phosphorylation as a
measure of receptor signalling. Using HEK293-T cells stably
expressing βc and transiently co-expressing IL3Rα SP2, IL3Rα
C76A,C195A and IL3Rα D197L (Supplementary Fig. 8), we
observed IL-3-dependent, co-immunoprecipitation (IP) of Flag-
tagged IL3Rα following βc IP that was associated with tyrosine
phosphorylation of βc (Fig. 6f). Surprisingly, deletion of the NTD
was associated with constitutive association of IL3Rα SP2 with βc
but the retention of IL-3-dependent tyrosine phosphorylation of
βc (Fig. 6f). Consistent with their SP2-like properties, IL3Rα
C76A,C195A, and to a lesser extent, IL3Rα D197L displayed
constitutive association with βc but retained IL-3-dependent
tyrosine phosphorylation of βc (Fig. 6f). These data strongly
suggest that a naturally constrained IL3Rα NTD prevents
spontaneous IL3Rα heterodimerisation with βc and could
potentially protect cells from unregulated signalling.
Discussion
We report here the three-dimensional atomic structures of the IL-
3 receptor α-subunit in complex with IL-3 and with the IL-3
K116W superkine, revealing the key interactions between recep-
tor and cytokine that compose site 1, the first and major recog-
nition step that initiates signalling in this family of receptors. Of
particular significance, is the finding through extensive analyses
by functional and MD simulation approaches that the NTD of
IL3Rα exhibits exquisite flexibility and a dynamic transition from
a high to a low mobility state upon cytokine binding that leads to
optimal ligand recognition, receptor dimerisation and signalling.
Since the NTD is also a feature of other members of the type I
cytokine receptor family, the results are likely to have general
implications for our understanding of how the NTDs function in
receptor assembly and signalling in other cytokine receptors.
Fig. 5 Ensemble of IL3Rα MD simulations in isolation and in complex with wild-type IL-3 and IL-3 K116W. a Snapshots from 75 ns (unliganded/apo IL3Rα)
and 100 ns (binary complexes) MD simulations overlaid via the IL3Rα CRM (ie, D2–D3). The mobility of the NTD progressively decreases when going from
the unliganded/apo IL3Rα (purple NTD, left), to the wild-type IL-3 binary complex (pink NTD, middle) and then to the IL-3 K116W binary complex (green
NTD, right). The IL3Rα CRM is shown as a dark grey molecular surface, the NTD is shown as a cartoon and the cytokine is depicted as a light grey
molecular surface. b Root-mean-square fluctuation (RMSF) of the Cα atoms in IL3Rα provides a measure of atom mobility around its average position
during the simulation. The data demonstrates that IL-3 K116W stabilises the NTD in the binary complex. Colour scheme and IL3Rα alignment as for a. The
location of the β-strands (black lines) and the disulphide bonds (red lines) are shown below the X-axis. c Comparison of full-length IL3Rα vs IL3Rα SP2
mobility in the wild-type IL-3 binary complex. Snapshots from the 100 ns MD simulations overlaid via the cytokine (grey molecular surface). IL3Rα shown
as a pink cartoon. Loss of the NTD has little impact upon the conformational mobility of the α-subunit. d Comparison of full-length IL3Rα vs IL3Rα SP2
mobility in the IL-3 K116W binary complex. Snapshots from the 100 ns MD simulations overlaid via the cytokine (grey molecular surface). IL3Rα shown as a
green cartoon. Loss of the NTD has a visible negative impact upon the conformational mobility of the α-subunit and it now resembles the wild-type IL-
3 system shown in c
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Fig. 6 IL3Rα mutations that perturb NTD placement also promote spontaneous receptor heterodimerisation. Snapshots from apo IL3Rα MD simulations
(75 ns wild-type, 100 ns mutants) overlaid via the IL3Rα CRM. Simulations initiated from both the closed and open wild-type apo IL3Rα conformations. a
When looking down onto the NTD, the range of conformations sampled by the apo wild-type IL3Rα closed (purple) and open (grey) starting
conformations, the C76A,C195A mutant (red) and D197L mutant (orange) can be clearly observed. b In the IL3Rα C76A,C195A mutant, the NTD twists
away from those conformations adopted by the closed (or open, not shown) apo wild-type IL3Rα. c In the IL3Rα D197L mutant, the NTD is also forced away
from D2 when compared to the conformations adopted by the open (or closed, not shown) apo wild-type IL3Rα. a–c the IL3Rα CRM is depicted as a dark
grey molecular surface and the NTD as a cartoon. View in b and c is a rotation of +90° about the X-axis from that shown in a. d Distance between the Cα
atoms of the C76–C195 inter-domain disulphide bond in the closed (purple) and open (grey) starting IL3Rα conformations compared to that in the C76A,
C195A mutant (red). The greater distance between the NTD and D2 for the C76A,C195A mutant is consistent with the reduced binding affinity for IL-3. e
Distance between the Cα atoms of S74-D197 in the closed (purple) and open (grey) starting conformations compared to that in the IL3Rα D197L mutant
(orange). In the closed wild-type IL3Rα conformation, S74 (NTD) and D197 (D2) form an inter-domain hydrogen bond, whereas the distance is too great in
the open conformation. The leucine side chain of the D197L mutant keeps the NTD and D2 apart in an open-like conformation. f HEK293T cells stably
expressing βc were transfected with either wild-type (WT), D197L, C76A,C195A or SP2 forms of Flag-tagged IL3Rα and stimulated with 1.5 μg ml−1 IL-3 for
45min at 4 °C. Cell lysates were immunoprecipitated with the βc antibody BION-1. Immunoprecipitates were immunoblotted with antibodies for IL3Rα
(anti-IL3Rα), phosphotyrosine (anti-TyrP) or total βc (anti-βc)
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A comparison of the IL-3 binary complexes showed that the
IL3Rα site 1a interaction involves the elbow region of D2 and D3
(Fig. 1a, c) that follows the paradigm established by the growth
hormone receptor25. In both complexes, a large interface was seen
with mutations of Q178, V201, Q204 and E276 in IL3Rα having a
significant effect upon wild-type IL-3 and IL-3 K116W signalling
(Supplementary Table 2). In contrast, mutations of N233 and
Y279 in IL3Rα had a significant effect upon wild-type IL-3 but
not IL-3 K116W signalling indicating an altered role for inter-
actions through these residues for IL-3 K116W. The major dif-
ference observed between the two complexes was the side chain of
the superkine’s W116 that inserts itself in a groove formed by
Q204 and Y279 of IL3Rα (Fig. 4), with mutation of Q204 redu-
cing both wild-type IL-3 and IL-3 K116W signalling (Supple-
mentary Table 2).
Both IL-3 binary complexes have a very similar site 1b inter-
face, yet they display important functional differences. The D-
strand of the IL3Rα NTD shows a close interaction with the AB
loop and CD loop of IL-3 (Fig. 1b). This helps to explain why
mutations of IL-3 E43 or D44 in the α2-helix of the AB loop
disrupt IL-3 function16, whereas mutation of adjacent residues in
the α2-helix including G42, Q45 and D46 enhances IL-3 binding
to IL3Rα as well as IL-3 function12,16. Furthermore, mutagenesis
of IL3Rα NTD residues K54, Y58 or G71 abolishes direct IL-3
binding11. The IL3Rα NTD EF loop is stabilised by an interaction
with the NTD B-strand residue Q37, which makes main-chain
contacts through its side chain with I73, and carbonyl interac-
tions with Q69 and F70. Mutation of IL3Rα Q37 also reduces IL-3
binding11, presumably as a result of changes to the NTD EF loop
conformation. Despite marked differences in the specific inter-
actions that comprise site 1b, the surface area between cytokine
and IL3Rα at the site 1b interface is relatively similar among the
related receptor complexes (34% in IL3Rα, 42% in GMRα (PDB
ID: 4RS111), 64% in IL5Rα (PDB ID: 3VA221), 47% in IL13Rα1
(PDB ID: 3BPO22) and 34% in IL13Rα2 (PDB ID: 3LB623))
(Fig. 2, Supplementary Fig. 2; see additional detail in Supple-
mentary Note 1) suggesting that it may be serving similar func-
tions in these other receptors. Interestingly, despite there being
essentially no difference in the way that IL-3 and IL-3 K116W
interacted with IL3Rα through site 1b, there were some crucial
differences in how mutation of many of these residues selectively
impaired the wild-type IL-3 function. Unlike IL3Rα interactions
with IL-3, the interaction with IL-3 K116W was not markedly
affected by mutations of K54, Y58 or G71 in the NTD (Fig. 3,
Supplementary Table 2) indicating that the K116W mutation has
stabilised the interaction with IL3Rα through distal effects on the
NTD.
In the published structure of IL3Rα bound to the blocking
antibody CSL362, we found the NTD in two distinct structural
forms, an open and a closed conformation11 that led us to
hypothesise that the IL3Rα NTD may be a highly mobile domain.
We now show by MD simulations that indeed the NTD is highly
mobile and that the presence of IL-3 stabilises the NTD in the
binary complex. The largest effect was observed for IL-3 K116W,
which restricts the conformational flexibility of the binary com-
plex (Figs. 4, 5a, b), probably as a result of W116 inducing a distal
effect that stabilises the engagement with the NTD thus
restricting domain mobility. This high mobility may be a general
feature of the NTD of the type I cytokine receptor family and a
major reason for the difficulty in their crystallisation, particularly
in the ligand-free state. The flexibility and high mobility of the
NTD may facilitate locking of the cytokine upon binding to site
1a and the appropriate presentation of the cytokine:α-subunit
complex to the signalling subunit. Similarly, in the interferon
(IFN) receptor, IFNAR1, conformational flexibility has been
observed in the IFN-bound and unliganded/apo structures.
Comparison of apo IFNAR1 with its IFN-bound form revealed a
large spatial rearrangement in the four extracellular subdomains
(SD1–SD4)27. Although the IFN ligand binds largely to the hinge
region between the IFNAR1 SD2 and SD3 domains, the NTD of
IFNAR1 (ie, SD1) moves downwards ~10 Å to interact with the
IFN ligand, further securing it to IFNAR1. The high mobility of
IFNAR1 is required for optimal ligand binding and the formation
of a ternary complex that then initiates trans-phosphorylation
between JAK1 and TYK228.
The importance of a conformationally restricted IL3Rα NTD is
further underscored by mutagenesis of the disulphide bond
between the NTD and D2 and of the aspartic acid at position 197.
These mutations abolished direct binding of IL-3 K116W and
reduced high-affinity binding and signalling in the presence of βc
(Tables 2, 3). Interestingly, mutations that perturb the position of
the NTD, or that completely delete the NTD, are associated with
spontaneous heterodimerisation of IL3Rα with βc, although
surprisingly, this spontaneous dimerisation does not result in
receptor tyrosine phosphorylation (Fig. 6f). These observations
are comparable with reports of preformed but non-signalling
dimers of receptors for growth hormone29 and erythropoietin30
that signal following ligand binding-induced conformational
changes in the receptor complex. In an analogous manner, the
architecture of the NTD-deficient or NTD-displaced IL3Rα may
promote association with βc to form inert IL3Rα:βc complexes
that only signal following conformational changes triggered by
the binding of IL-3. While tyrosine phosphorylation of the βc
receptor was strictly dependent upon IL-3 stimulation, other
forms of receptor signalling could be associated with spontaneous
heterodimerisation of IL3Rα and βc. Additionally, in cells
expressing wild-type IL3Rα, the NTD may serve a protective role
by preventing signalling from receptor association arising in the
absence of ligand.
The relatively high expression of IL3Rα in a number of leu-
kaemias has presented a window of opportunity to develop new
therapeutic approaches directed to IL3Rα such as monoclonal
antibodies (MAbs)8,31,32, T cells engineered to express chimeric
antigen receptors (CAR T cells)33 and toxin conjugates with IL-
Table 3 Enhanced site 1a interactions do not fully compensate for perturbations of functional interactions through the NTD
IL-3 IL-3 K116WIL3Rα
n ED50 (ngml−1) p n ED50 (ngml−1) p
P
Wild type 6 0.29± 0.11 — 6 0.37± 0.10 — 0.58
SP2 3 6.94± 1.19 0.0003 3 2.19± 0.15 <0.0001 0.02
C76A,C195A 3 12.17± 2.02 0.0002 3 2.51± 0.49 0.002 0.01
D197L 3 1.71± 0.08 0.0002 3 0.60± 0.13 0.27 0.002
Functional activity of IL3Rα mutants was measured in IL-3 or IL-3 K116W dose–response proliferation assays using FDH cell lines transduced to co-express the βc subunit with either wild-type or mutant
forms of IL3Rα. Half-maximal responses (ED50) were calculated from each experiment and averaged. Errors represent SEM from the indicated number (n) of experiments. Statistical significance of
functional response between wild-type IL3Rα and the mutant forms of IL3Rα (p) or between IL-3 and IL-3 K116W (P) was determined using a two-tailed paired t test. Related to Figs. 5, 6, Supplementary
Fig. 8 and Table 2
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02633-7 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:386 |DOI: 10.1038/s41467-017-02633-7 |www.nature.com/naturecommunications 11
334–37. The latter was originally only partially successful as half
the samples proved resistant to the fusion protein38. The potency
of the toxin-IL-3 fusion protein was improved dramatically by
introducing the K116W substitution into the IL-3 portion38–40.
The insights described in our work explain the potency of the IL-
3 K116W superkine and suggest new avenues for further protein
engineering of even more potent superkines.
In comparing the effects of IL3Rα mutations on IL-3 and IL-3
K116W binding and signalling, we noted that for cells expressing
endogenous IL-3 receptors (such as TF-1 cells) there is, as pre-
viously reported by us and others, a sixfold increased potency of
the IL-3 superkine (Table 2, Supplementary Fig. 6a). However, in
cells overexpressing IL3Rα (such as engineered CTLL-2 or FDH
cell lines, TF-1Hi cells and COS cells), this difference was dimin-
ished or absent (Fig. 3, Supplementary Fig. 6a, Tables 2, 3, Sup-
plementary Table 2). The observation that IL3Rα expression levels
vary widely among different primary cell populations41 suggests
the likelihood of differences in IL-3 sensitivity among these cell
populations. This may also have implications in AML where the
AML leukaemic stem/progenitor cells express elevated levels of
IL3Rα7,8, but may also indicate differences in the composition or
form of the endogenous IL-3 receptor. For instance, it is known
that transcripts for the IL3Rα SP2 splice variant are expressed by
TF-1 cells24 and this could contribute to reduced IL-3 binding and
function compared to cells only expressing full-length IL3Rα.
In summary, our results highlight the unique dynamics and
role of the NTD in IL-3 signalling and suggest the purpose of its
conservation among members of the type I cytokine receptor
family.
Methods
Production of recombinant IL-3:sIL3Rα binary complexes. We prepared wild-
type IL-3 and IL-3 K116W binary receptor complexes using partially glycosylated
variants of the IL3Rα extracellular domain and truncated wild-type IL-3 or IL-3
K116W. DNA fragments encoding soluble IL3Rα ΔN5 (sIL3Rα; residues L20-S307
of the expressed peptide with the N212Q mutation) or soluble βc ΔN3 (sβc;
residues E25-S438 of the expressed peptide with the N346Q mutation) were cloned
into the pFastBac1 vector (Invitrogen). The resulting plasmids were transformed
into the DH10Bac Escherichia coli strain from which recombinant bacmid DNA
was isolated and transfected into Sf9 insect cells (ATCC CRL-1711) using Cellfectin
reagent (Invitrogen). Following three rounds of recombinant virus propagation,
large-scale expression was performed by infection of Sf9 cells grown in Sf-900 II
serum-free medium (Life Technologies). The supernatant was collected after 5 days
and recombinant proteins affinity-purified using HiTrap NHS-activated HP col-
umns (GE Healthcare) coupled to the IL3Rα-specific MAb 9F542 or the βc-specific
MAb BION-143. Bound protein was eluted using 500 mM NaCl, 50 mM phos-
phoric acid pH 2.4 and the eluted protein concentrated and further purified by
preparative size exclusion chromatography (SEC) using a Superdex 200 column
(26 × 600 mm, GE Healthcare) operated at 2 ml min−1 with 150 mM NaCl, 50 mM
sodium phosphate pH 7.0 as running buffer44. Binding and functional studies with
wild-type IL-3 demonstrate that the N212Q mutation has no impact on the
function of full-length IL3Rα (Supplementary Fig. 3c, d). Wild-type or K116W
versions of human IL-3, comprising residues W13 to Q125 of the mature peptide
with a W13Y mutation and a GAMGS N-terminal tail arising from the expression
plasmid, were purified from E. coli45. BL21 CodonPlus (DE3)-RIPL cells trans-
formed with pETNusH expression vectors encoding Nus-6xHis-TEV:IL-3 fusion
proteins, were cultured to an OD600 of 0.6 and induced with 0.1 mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) at 23 °C for 16 h. Cells were lysed and Nus-
6xHis-TEV:IL-3 fusion proteins affinity-purified using HisTrap FF columns (GE
Healthcare). Fusion proteins were concentrated, dialysed against 50 mM Tris-HCl
pH 8.0, adjusted to 1 mM dithiothreitol, 0.5 mM EDTA and incubated with TEV
protease at 23 °C for 16 h. IL-3 was purified from the TEV digest by preparative
SEC then adjusted to 0.1% v v−1 trifluoroacetic acid, 1% v v−1 acetic acid and
further purified by reversed-phase chromatography using an Aquapore RP300
reversed-phase column (4.6 × 100 mm, PerkinElmer) equilibrated in buffer A (0.1%
v v−1 trifluoroacetic acid) and eluted using a linear gradient from 0 to 100% buffer
B (0.085% v v−1 trifluoroacetic acid in acetonitrile). Fractions containing purified
hIL-3 were lyophilised, resuspended in PBS and sterilised using Corning Spin-X
filters (Sigma-Aldrich). We, and others, have previously demonstrated that com-
pared to full-length recombinant IL-3, the truncated IL-3 has equivalent
bioactivity45.
A binary complex consisting of wild-type IL-3 and sIL3Rα ΔN5 was isolated by
SEC of a 2:1.5:1 molar ratio mixture of IL-3:sIL3Rα ΔN5:sβc ΔN3 (Supplementary
Fig. 1a). Using a similar strategy, a binary complex consisting of IL-3 K116W and
sIL3Rα ΔN5 was isolated by SEC of a 1.6:1 molar ratio mixture of IL-3 K116W:
sIL3Rα ΔN5 (Supplementary Fig. 1b).
Analysis of sIL3Rα N-linked glycosylation mutants. Soluble IL3Rα com-
plementary DNA (cDNA) with a C-terminal 6xHis tag (sIL3Rα-6xHis) was cloned
into the pcDNA3.1 expression vector (Invitrogen) and asparagine to glutamine
mutations generated by PCR at the six predicted N-linked glycosylation sites.
Freestyle™ 293 suspension cells (Invitrogen) were transiently transfected with the
pcDNA:sIL3Rα-6xHis plasmids11 and the resulting supernatants immunoblotted
with 0.9 μg ml−1 of the anti-IL3Rα MAb, 7G342 and 1 μg ml−1 of goat-anti-mouse
IgG - fluorescein isothiocyanate (IgG-FITC (Thermofisher 62-6511)) or 0.25 μg ml
−1 of FITC-conjugated anti-His tag antibody (Anti-6xHis Genescript cat no.
A01620).
Structure determination of IL-3:IL3Rα binary complexes. Crystallisation was
performed using the hanging drop vapour diffusion method at 4 °C. Crystallisation
trials of IL-3 K116W:IL3Rα were set up using the protein crystallisation screen
JCSG46 at the CSIRO C3 crystallisation facility (http://crystal.csiro.au) with the
protein at a concentration of 12 mgml−1. Protein of 0.15 μl was mixed with 0.15 μl
of crystallisation reagent and hung over 50 μl of reservoir solution. Tetragonal
crystals appeared after 5 days in 18–23% (w v−1) PEG 8000, 200 mM NaCl and 100
mM citrate-phosphate buffer pH range 4.6–5. After screening around this condi-
tion, the best crystals were obtained in 20% PEG 8000, 200 mM NaCl and 100 mM
citrate-phosphate buffer pH 4.8. The crystals diffracted to a resolution of 2.4 Å in
the hexagonal space group P61. The space group and cell dimensions were con-
sistent with there being one complex in the asymmetric unit giving a Matthews
coefficient of 3.0 Da Å−3 and an estimated solvent content of 65%. Before data
collection the crystals were dipped consecutively into 5% (v v−1), 10% (v v−1), 15%
(v v−1) cryomix (8.4% each of ethylene glycol, glycerol, 2-methyl-2,4-pentanediol,
sorbitol, PEG 400, and sucrose) in crystallisation buffer.
Data were collected on the MX2 beamline at the Australian Synchrotron
(Clayton, Victoria). Data collection was controlled using Blue-Ice software47 and
processed with the HKL2000 suite48. The structures were solved with the program
Phaser49 initially trialling a range of search models including IL3Rα open and
closed conformations (PDB ID: 4JZJ), IL13Rα1 (PDB ID: 3BPO), IL13Rα2 (PDB
ID: 3LB6), IL5Rα (PDB IDs: 3QT2, 3VA2), and the partial GMRα structure from
the ternary GM-CSF complex (PDB ID: 3CXE). The final model used for molecular
replacement for the IL-3 K116W binary complex was the nuclear magnetic
resonance structure for IL-3 (PDB ID: 1JLI) and the IL13Rα2 receptor (PDB ID:
3BL6) as separate search components. The results from Phaser gave a final
translation function Z-score of 9.6. One IL-3 K116W:IL3Rα complex was found in
the asymmetric unit. Loop regions were manually built in place using COOT50 and
subsequent rounds of refinement using REFMAC51. Residues spanning 27–293 of
IL3Rα and 12–123 in IL-3 were identified with clear and unambiguous electron
density observed at the IL-3:IL3Rα interface. Electron density was not observed for
residues 42–50 and 86–90 in IL3Rα, which are located in flexible loop regions.
Electron density representing glycan moieties was observed at glycosylation sites
N80 and N218 in IL3Rα. The stereochemical quality of the final model correlates
well with structures at similar resolutions with only 0.5% of residues in the
disallowed regions of the Ramachandran plot. Other stereochemical parameters
were are all better than the allowed ranges defined by PROCHECK52. Data and
refinement statistics are listed in Table 1 and stereo images of portions of the
electron density maps in Supplementary Fig. 10. The PISA (Protein Interfaces,
Surfaces and Assemblies) server http://www.ebi.ac.uk/msd-srv/prot_int/pistart.
html was used for all protein-ligand surface interaction calculations.
We have previously tried exhaustive crystallisation screening and construct
optimisation of wild-type IL-3:IL3Rα for many years without success. Our results
described here provide a possible explanation: the mobility of the NTD inhibits
crystallisation. Crystals of wild-type IL-3:IL3Rα did not grow under the same
condition as IL-3 K116W:IL3Rα; we were only able to crystallise IL-3:IL3Rα when
microcrystals of IL-3 K116W:IL3Rα were used to seed crystals of wild-type IL-3:
IL3Rα. Drops comprised 0.2 μl of seed solution, 0.4 μl of protein and 0.4 μl of
crystallisation reagent and hung over 1 ml of reservoir solution. Tooth-shaped
crystals appeared after 5 days in 20–22% PEG 8000, 200 mM NaCl and 100 mM
citrate-phosphate buffer pH range 4.8–5. The crystals diffracted to a resolution of
2.7 Å in the hexagonal space group P6522. The space group and cell dimensions
were consistent with there being two complexes in the asymmetric unit giving a
Matthews coefficient of 2.8 Da Å−3 and an estimated solvent content of 58%. Before
data collection, the crystals were cryoprotected as described for the IL-3 K116W:
IL3Rα crystals.
The structure of wild-type IL-3:IL3Rα was solved using the refined model of IL-
3 K116W:IL3Rα and the programs described above. The results from Phaser gave a
final translation function Z-score of 47.1. Two wild-type IL-3:IL3Rα complexes
were found in the asymmetric unit. Building and refinement was completed as
described above. Residues spanning 25–294 of IL3Rα and 13–121 in wild-type IL-3
were identified with clear and unambiguous electron density observed at the IL-3:
IL3Rα interface. Chains G and I were the most complete of the two copies, however
electron density was not observed for residues 48 and 143–146 in IL3Rα, which are
all located in flexible loop regions. Electron density representing glycan moieties
was observed at glycosylation sites N80, N109 and N218 in IL3Rα. The
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stereochemical quality of the final model correlates well with structures at similar
resolutions with only 0.3% of residues in the disallowed regions of the
Ramachandran plot. Other stereochemical parameters were all better than the
allowed ranges defined by PROCHECK52. Data and refinement statistics are listed
in Table 1.
Molecular dynamics simulations. Fully atomistic simulations of (a) the apo
IL3Rα closed and open conformations (PDB ID: 4JZJ11), (b) wild-type IL-3:IL3Rα
binary complex (this work), (c) IL-3 K116W:IL3Rα binary complex (this work), (d)
wild-type IL-3 extracted from the binary complex crystal structure, (e) IL-3 K116W
extracted from the binary complex crystal structure, (f) modelled SP2 versions of
the wild-type IL-3 and IL-3 K116W binary complexes, (g) modelled apo IL3Rα
D197L and (h) modelled apo IL3Rα C76A,C195A were carried out. Crystal-
lographic waters, sugars and ions and so on were removed from the starting crystal
structures. Missing residues or side chains were modelled in using either SYBYL-X
2.1.1 (Certara L. P., http://www.tripos.com) or Coot version 0.753. The SP2 version
of IL3Rα (Supplementary Fig. 1c)24 was modelled using SYBYL-X 2.1.1. The
D197L and C76A,C195A IL3Rα mutations were made in silico using SYBYL-X
2.1.1. Hydrogens were added and the protein termini capped with neutral acid and
amide groups. Titratable residues were left in their dominant protonation state at
pH 7.0. All simulations were performed using the program NAMD-2.1054 with the
CHARMM3655 force field at a constant temperature of 310 K and atmospheric
pressure. Ions were added to balance charge and give an ionic concentration of 150
mM NaCl. The TIP3P water model56 was used in rhombic dodecahedral simula-
tion cells with at least 12-Å separation between the protein and its periodic image.
For long range interactions, the Particle Mesh Ewald method was used with a
switching distance of 10 Å and cutoff distance of 12 Å. Simulations were typically
performed as follows: the energy was minimised for 5000 iterations, followed by
system equilibration for 1 ns and then production simulations of 75–200 ns were
carried out. The positions of all atoms in the system were saved every 10 ps for later
analysis and visualisation using the programs mdtraj57 and VMD58.
Functional studies with IL3Rα mutants. Human IL3Rα cDNA was cloned into
the pcDNA3.1 (Invitrogen) or pSG5 (Stratagene) expression vectors and mutations
generated by PCR11. For site 1 functional studies (Fig. 3, Supplementary Table 2)
and studies of the NTD interaction (Fig. 6, Table 3), we used an IL3Rα cDNA that
encodes a splice variant which lacks three nucleotides and changes N144 and R145
to K144 compared to the sequence of the sIL3Rα used for the structural studies
(Supplementary Fig. 1c). The two variants are indistinguishable in IL-3 binding and
functional studies11. For the spontaneous heterodimerisation studies (Fig. 6, Sup-
plementary Fig. 8), we used an IL3Rα cDNA engineered to include a C-terminal
Flag epitope tag (…VQKTALDYKDDDDKA-COOH) following the final threonine
residue of full-length IL3Rα. Human βc cDNA was cloned in the pSG5 vector.
Wild-type and mutant IL3Rα was subcloned into the retroviral expression
vector pRufHygro and the pRufHygro:IL3Rα plasmids co-transfected into
HEK293-T (ATCC CRL-3216) cells with the pEQ-Eco packaging plasmid59 using
Lipofectamine 2000 (Invitrogen) to generate recombinant retrovirus. Wild-type βc
cDNA was cloned in the pRufPuro retroviral expression vector and the pRufPuro:
βc plasmid used to generate recombinant retrovirus by the same approach.
Retrovirus was collected from conditioned medium at day 3 post transfection by
centrifugation at 1500 r.p.m. for 5 min and the supernatant 0.45 μm filtered. The
CTLL-2 cell line (ATCC TIB-214) is maintained in RPMI media (Gibco)
supplemented with antibiotics, 10% (v v−1) foetal bovine serum, 1 mM sodium
pyruvate (Gibco), 55 μM 2-mercaptoethanol (Gibco) and 400 Uml−1 murine IL-2.
CTLL-2 cells lines were made by transduction with retrovirus. Non-tissue culture
treated plates (Falcon) were coated with 32 μg ml−1 RetroNectin (Takara) overnight
at 4 °C, blocked at room temperature with 2% w v−1 BSA for 1 h and then
centrifuged with retrovirus at 3500 r.p.m. for 1 h at 37 °C. The virus coated plates
were then incubated with 1 × 105 CTLL-2 cells in 1 ml complete media overnight at
37 °C and a second round of transduction was performed the following day using
fresh retrovirus. Media was changed 24 h following the second round of
transduction, and 48 h following this, antibiotic selection was added as described
below. Pools of resistant cells grew out over 7–10 days and cells were sorted for
receptor expression by flow cytometry. CTLL-2 cells were initially transduced to
express βc, selected with puromycin (selection 2 μg ml−1, maintenance 1 μg ml−1)
and sorted for βc expression by flow cytometry60. Subsequently the CTLL-2:βc cells
were transduced to express the IL3Rα variants, selected with hygromycin (selection
1000 μg ml−1, maintenance 500 μg ml−1) and sorted for IL3Rα expression by flow
cytometry60.
The HoxA9-immortalised cell line, FDH, was generated by transduction of
foetal liver cells from mice lacking βc and βIL-361 using a pFTREtight MCS
rtTAadvanced GFP lentivirus encoding a doxycycline-inducible HoxA9-Flag
expression cassette62. The FDH cell line is maintained in IMDM media (Gibco)
supplemented with antibiotics, 10% (v v−1) foetal bovine serum, 100 ng ml−1
murine stem cell factor and 0.5 μg ml−1 doxycycline hyclate (Sigma). FDH cells
were transduced with βc, selected with puromycin (selection 2 μg ml−1,
maintenance 1 μg ml−1), and subsequently transduced to express the IL3Rα
variants and selected with hygromycin (selection 500 μg ml−1, maintenance 250 μg
ml−1), with sorting as described above.
Cell proliferation was assessed using CellTiter 96® AQueous (Promega)
following the manufacturer's protocol. Data were analysed using GraphPad Prism
to determine ED50 values.
Statistical methods. A two-tailed unpaired t test was used for calculation of
significance in binding and functional studies. For figures, error bars are SEM.
Cell-surface IL-3-binding assays. COS-7 cells (ATCC CRL-1651) were electro-
porated with pcDNA3.1:IL3Rα plasmids encoding wild-type or mutant IL3Rα,
either alone or in the presence of the pSG5H:βc plasmid encoding human βc60.
Cell-surface expression of receptor subunits was confirmed by flow cytometry.
Wild-type IL-3 and IL-3 K116W were radioiodinated with 125I (PerkinElmer)
using Pierce pre-coated iodination tubes (Thermo Scientific). Saturation binding
assays were performed on transfected COS cells, CTLL-2 cell lines, TF-1 cells or
TF-1Hi cells using radioiodinated IL-360. Dissociation constants were calculated
using the EBDA and LIGAND programs63 (KELL Radlig, Biosoft, UK). Repre-
sentative data from IL-3-binding assays on TF-1 and TF-1Hi cells lines were also
analysed by nonlinear regression using GraphPad Prism and yielded essentially
identical dissociation constants.
Assessing the cell-surface expression of IL-3 receptor subunits. Cell-surface
expression of receptor subunits was assessed by flow cytometry using 10 μg ml−1 of
MAb’s specific for IL3Rα, including 7G3, 9F542 and MAB301 (R&D Systems cat
no. MAB301), and for βc, 1C164. Bound antibodies were stained using 5 μg ml−1 of
PE conjugated goat-anti-mouse IgG (Southern Biotech cat. no. 1030-09). MAb’s
7G3 and 9F5 bind IL3Rα NTD and MAB301 binds IL3Rα D2–D3. An irrelevant
mouse antibody 1B5 (anti-Giardia IgG1) was used as a negative control.
IL3Rα expression and IL-3 function on TF-1 and TF-1Hi cells. The human
erythroleukaemia cell line, TF-165 (ATCC CRL-2003) was transduced with lenti-
viral vectors encoding GFP alone or IL3Rα and GFP26 to produce the TF-1EV and
TF-1Hi lines, respectively. Cell-surface expression levels of IL3Rα and βc was
measured by flow cytometry. Wild-type IL-3- and IL-3 K116W-mediated pro-
liferation of TF-1 EV and TF-1Hi lines was assessed using CellTiter 96® AQueous
(Promega). Data were analysed using GraphPad Prism to determine ED50 values.
Constitutive association of IL3Rα NTD mutants with βc. HEK293-T cells were
stably transduced with pRufPuro:βc to express wild-type human βc as described
above. The HEK293-T-βc cells were transfected with 2–10 μg of pcDNA3.1:IL3Rα
Flag plasmids encoding wild-type or mutant IL3Rα using Lipofectamine 2000
(Invitrogen). Cells were collected after 2 days and stimulated with 1.5 μg ml−1 IL-3
for 45 min on ice prior to lysis in NP-40 lysis buffer (1% NP-40 (v v−1), 150 mM
NaCl, 50 mM Tris-HCl pH 8.0 and 10% (v v−1) glycerol) for 20 min on ice. The βc
complexes were immunoprecipitated from clarified lysate using 1C1-conjugated
Sepharose beads, washed three times with lysis buffer, fractionated by SDS-PAGE
and immunoblotted with antibodies for IL3Rα-Flag (1 μg ml−1 anti-Flag M2:HRP,
Sigma cat no. A8592), βc (1.8 μg ml−1 BION-143) and 0.1 μg ml−1 goat-anti-mouse:
HRP (Pierce cat. no. 31437) or phosphorylated tyrosine residues (0.25 μg ml−1 anti-
phosphotyrosine:HRP, BD Transduction Laboratories cat. no. 610012). (Uncrop-
ped scan of immunoblot Supplementary Fig. 9). Cell-surface expression of receptor
subunits was confirmed by flow cytometry of collected cells as described above.
Data availability. Atomic coordinates and structure factors of the wild-type IL-3
and IL-3 K116W binary receptor complexes have been deposited in the Protein
Data Bank under the ID codes 5UV8 and 5UWC, respectively. All other data are
available from the corresponding authors upon reasonable request.
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